Pharmaceutical composition for preventing or treating metabolic dysfunction-associated steatotic liver disease, comprising enavogliflozin as active ingredient
Inabogliflozin is used in a pharmaceutical composition to treat fatty liver disease and type 2 diabetes by reducing hepatic steatosis, addressing the inadequacies of existing treatments and showing significant improvements in fatty liver disease prevalence and liver steatosis indices.
Patent Information
- Application Number
- PCT/KR2026/005854
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-17
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments do not effectively address fatty liver disease associated with metabolic dysfunction, despite the known efficacy of inabogliflozin in lowering blood glucose levels and urinary glucose excretion.
Inabogliflozin is used as an active ingredient in a pharmaceutical composition to prevent or treat metabolic dysfunction-associated steatotic liver disease (MASLD), which can be administered alone or in combination with other diabetes medications to enhance therapeutic effects.
Inabogliflozin significantly reduces hepatic steatosis indicators, improving fatty liver disease and type 2 diabetes in patients with MASLD, demonstrating a 32% reduction in prevalence and a lower average liver steatosis index compared to placebo and similar drugs.
Smart Images

Figure KR2026005854_12112026_PF_FP_ABST
Abstract
Description
Pharmaceutical composition for the prevention or treatment of fatty liver disease associated with metabolic dysfunction, comprising inabogliflozin as an active ingredient
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) comprising inabogliflozin as an active ingredient.
[0002] SGLT-2 (sodium glucose cotransporter 2) is a transporter responsible for the excessive reabsorption of glucose in the kidneys, along with SGLT-1 (sodium glucose cotransporter 1), with SGLT-2 playing the majority of the role. Therefore, when SGLT-2 inhibitors suppress the SGLT-2 transporter, the amount of glucose excreted in the urine increases, which ultimately lowers blood glucose levels and further excretes the calories contained in the glucose, resulting in weight loss.
[0003] One of the drugs developed as an SGLT-2 inhibitor that can be usefully used as a treatment for type 2 diabetes due to such effects is Enavogliflozin, represented by the following structural formula (Chemical Formula 1), and has been disclosed in Korean Patent Publication No. 2014-0022086 (Patent Document 1).
[0004] [Chemical Formula 1]
[0005]
[0006] Compound Name: (2S,3R,4R,5S,6R)-2-(7-chloro-6(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
[0007] Inabogliflozin (DWP16001) is a drug currently undergoing Phase 3 clinical trials, and results from Phase 2 trials confirmed a statistically significant blood glucose-lowering effect compared to placebo in all groups of inabogliflozin 0.1 mg, 0.3 mg, and 0.5 mg.
[0008] This is evaluated as showing excellent efficacy in urinary glucose excretion (glucose excreted in urine) at a very low dose, which is 1 / 100th the dose of drugs in the same class.
[0009] However, it has not yet been reported that inabogliflozin is useful for preventing or treating fatty liver disease associated with metabolic dysfunction.
[0010] The inventors have completed the present invention by confirming that inabogliflozin can prevent or treat fatty liver disease associated with metabolic dysfunction.
[0011] Therefore, the objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of fatty liver disease associated with metabolic dysfunction, comprising inabogliflozin as an active ingredient.
[0012] The present invention will be described in more detail below.
[0013] The present invention provides the use of inabogliflozin for the prevention or treatment of fatty liver disease related to metabolic dysfunction, a pharmaceutical composition for the prevention or treatment of fatty liver disease related to metabolic dysfunction comprising inabogliflozin, and a method for the prevention or treatment of fatty liver disease related to metabolic dysfunction comprising administering an effective amount of inabogliflozin to a subject who requires it.
[0014] As used herein, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) refers to a disease characterized by hepatic steatosis accompanied by at least one metabolic dysfunction. This is a new term agreed upon by major liver societies worldwide in 2023 to replace the existing Non-alcoholic Fatty Liver Disease (NAFLD), emphasizing 'metabolic dysfunction,' which is a core pathophysiological characteristic of the disease.
[0015] MASLD refers to cases where fat deposition in the liver is confirmed through imaging or histological examinations, and one or more of the following indicators of metabolic dysfunction are met: (1) having type 2 diabetes mellitus; (2) having two or more metabolic risk factors among impaired fasting glucose (100–125 mg / dL), increased waist circumference (male ≥ 90 cm, female ≥ 80 cm, Asian standard), hypertriglyceridemia (triglycerides ≥ 150 mg / dL or taking lipid-lowering agents), low HDL-cholesterol (male < 40 mg / dL, female < 50 mg / dL), hypertension (≥ 130 / 85 mmHg or undergoing hypertension treatment), and increased HOMA-IR (HOMA-IR ≥ 2.5 or the upper quartile of the population).
[0016] MASLD is closely associated with metabolic syndrome, type 2 diabetes, and obesity, going beyond simple liver fat accumulation, and can progress to metabolic dysfunction-associated steatohepatitis (MASH) if accompanied by inflammation and hepatocellular damage. MASH is an intensified form of MASLD with a high risk of progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma.
[0017] The following examples present the results of an integrated analysis of the effect of inabogliflozin on improving hepatic steatosis indicators using data from three Phase 3 clinical trials of inabogliflozin conducted on a total of 555 patients with type 2 diabetes. Approximately 50% of the patients with type 2 diabetes participating in the clinical trials were found to have fatty liver at the start of the study (278 out of a total of 555 patients based on the Hepatic Steatosis Index (HSI)). Patients who took 0.3 mg of inabogliflozin daily for 24 weeks showed a 32% and 25% reduction in the prevalence of fatty liver, as assessed by the Hepatic Steatosis Index (HSI) and Framingham Steatosis Index (FSI), respectively, compared to baseline, confirming that inabogliflozin significantly improved the prevalence of hepatic steatosis.
[0018] In the placebo-controlled study, the inabogliflozin treatment group showed a significant difference, with the prevalence of fatty liver decreasing from 48.0% to 16.0% based on the hepatic steatosis index and from 41.3% to 16.0% based on the Framingham steatosis index, respectively, and the mean scores improving by -3.72 (p<0.0001) and -1.16 (p=0.0006), respectively, compared to the placebo group.
[0019] In comparison with dapagliflozin, a drug of the same class, inabogliflozin showed a significant improvement effect, with the average liver steatosis index being 1.02 points lower (p=0.0257).
[0020] Therefore, inabogliflozin can be usefully used for the prevention or treatment of MASLD.
[0021] In one embodiment of the present invention, the MASLD may be accompanied by type 2 diabetes or impaired fasting blood glucose.
[0022] In one embodiment of the present invention, it may be for the improvement of a metabolic abnormal state in which the Hepatic Steatosis Index (HSI) exceeds 30 or the Framingham Steatosis Index (FSI) is -1.2 or higher. In one embodiment of the present invention, it may be for the improvement of a metabolic abnormal state in which the HSI exceeds 36 or the FSI is -1.2 or higher. In the following examples, it was shown that inabogliflozin can significantly reduce these indices in patients with a metabolic abnormal state in which the HSI exceeds 30 or 36 or the FSI is -1.2 or higher.
[0023] The present invention also provides the use of inabogliflozin for the prevention or treatment of type 2 diabetes in MASLD patients, a pharmaceutical composition for the prevention or treatment of type 2 diabetes in MASLD patients comprising inabogliflozin as an active ingredient, and a method for the prevention or treatment of type 2 diabetes in MASLD patients comprising administering an effective amount of inabogliflozin to a subject who requires it.
[0024] A pharmaceutical composition containing inabogliflozin as an active ingredient can be used in the form of single administration or combination administration.
[0025] Inabogliflozin alone is sufficient to prevent or treat MASLD. However, diabetes medications including inabogliflozin are administered in combination for various purposes, and since they may exhibit complementary or synergistic effects when administered in combination, pharmaceutical compositions containing inabogliflozin can be administered in combination with other diabetes medications or other MASLD medications.
[0026] In one embodiment, a pharmaceutical composition containing inabogliflozin may be intended for co-administration with metformin.
[0027] In another embodiment, a pharmaceutical composition containing inabogliflozin may be intended for co-administration with a DPP4 inhibitor.
[0028] Although not limited thereto, for example, the above DPP4 inhibitor may be gemigliptin.
[0029] In another embodiment, the above co-administration may be co-administration with two or more different drugs. For example, a pharmaceutical composition containing inabogliflozin may be intended for co-administration with metformin and a DPP4 inhibitor.
[0030] Alternatively, a pharmaceutical composition containing inabogliflozin may be administered in combination with a sulfonylurea insulin secretagogue.
[0031] In another embodiment, a pharmaceutical composition containing inabogliflozin may be administered in combination with insulin.
[0032] In one embodiment, for convenience of co-administration, a pharmaceutical composition containing inabogliflozin may be formulated together with metformin and / or a DPP4 inhibitor.
[0033] As used herein, the term “prevention” refers to any act of suppressing or delaying the onset of fatty liver disease associated with metabolic dysfunction by administering a pharmaceutical composition according to the present invention.
[0034] Furthermore, as used herein, the term “treatment” refers to any act in which fatty liver disease associated with metabolic dysfunction is improved or beneficially altered by the administration of a pharmaceutical composition according to the present invention.
[0035] The dose of inabogliflozin that may be used for the prevention or treatment of MASLD or for the prevention or treatment of type 2 diabetes in patients with MASLD is not specifically limited and may be appropriately adjusted based on the severity of the patient's disease, weight, age, gender, presence or absence of other complications, etc.
[0036] The duration of administration of inabogliflozin can be appropriately adjusted by the clinician based on the preventive or therapeutic effect of inabogliflozin administration on MASLD or the preventive or therapeutic effect of inabogliflozin administration on type 2 diabetes in patients with MASLD.
[0037] In one embodiment of the present invention, the treatment method may be to administer a pharmaceutical composition for the prevention or treatment of MASLD or for the prevention or treatment of type 2 diabetes in patients with MASLD in combination with metformin and / or gemigliptin.
[0038] Since the above-mentioned methods for the prevention or treatment of MASLD or for the prevention or treatment of type 2 diabetes in MASLD patients utilize the pharmaceutical composition of the present invention, any overlapping details between the two are omitted to avoid excessive description in the specification.
[0039] Inabogliflozin used as an active ingredient in the present invention can be synthesized through known prior art. In the present invention, inabogliflozin may be in a crystalline or amorphous form. For example, inabogliflozin may be inabogliflozin crystalline form A, crystalline form B, crystalline form C, crystalline form D, crystalline form E, or inabogliflozin amorphous form, which are reported to have the following X-ray diffraction spectra through Korean Patent Publication No. 2017-0142904 or Korean Patent Application No. 2022-0123673.
[0040] Crystalline Form A: A crystalline having an X-ray diffraction (XRD) spectrum including peaks at 2θ values selected from 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, and 25.1°±0.2°, having a crystalline form
[0041] Crystalline Form B: A crystalline form having an X-ray diffraction (XRD) spectrum including peaks at 2θ values selected from 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, and 23.5°±0.2°, having a peaks at 2θ values.
[0042] Crystalline form C: Crystalline form having an X-ray diffraction (XRD) spectrum including peaks at 2[θ values selected from 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, and 21.9°±0.2°
[0043] Crystalline form D: Crystalline form having an X-ray diffraction (XRD) spectrum including peaks at 2θ values selected from 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, and 21.1°±0.2°
[0044] Crystalline form E: Crystalline form having an X-ray diffraction (XRD) spectrum including peaks at 2θ values selected from 4.93°±0.2°, 6.12°±0.2°, 7.43°±0.2°, 8.89°±0.2°, 9.74°±0.2°°, 14.79°±0.2°, 15.79°±0.2°, 16.11°±0.2°, 19.79°±0.2°, and 22.83°±0.2°
[0045] The above crystal forms A, B, C, D, and E can each be identified by an X-ray diffraction spectrum having four or more, for example, four, five, six, seven, or eight or more peaks at the 2[θ value presented above.
[0046] Although not limited thereto, a pharmaceutical composition containing inabogliflozin according to the present invention may have the composition of a pharmaceutical composition of PCT / KR2022 / 014640.
[0047]
[0048] *For example, the pharmaceutical composition of the present invention may be a pharmaceutical composition comprising inabogliflozin or its pharmaceutically acceptable salt, excipients, disintegrants, and binders as active ingredients, wherein the average particle size of inabogliflozin is 15 μm or less.
[0049] In a specific embodiment of the present invention, the average particle size of inabogliflozin may be 15 µm or less, preferably 10 µm or less.
[0050] When the average particle size of inabogliflozin exceeds 15 µm, the 5-minute dissolution rate is very low at less than 40% of the total content of inabogliflozin, and the 30-minute dissolution rate is also less than 80%, so the final dissolution rate is found to be unsuitable.
[0051] If finer particle size reduction of the drug is required, the drug can be ground using conventional mills capable of fine particle reduction, such as Z-mills, hammer mills, ball mills, and fluid energy mills. Additionally, the particle size of the drug can be further refined using size classification methods, such as sieving or air current classification. Methods for controlling the desired particle size are well known in the art. For example, refer to the following literature: [Pharmaceutical dosage forms: volume 2, 2nd edition, Ed.: HALieberman, L. Lachman, JBSchwartz (Chapter 3: SIZE REDUCTION)].
[0052] In this specification, the particle size of a drug is expressed based on a particle size distribution such as D(X) = Y (where X and Y are positive numbers). D(X) = Y means that when the particle size distribution of a drug obtained by measuring the particle diameter of a drug within a formulation is represented by a cumulative curve, the particle diameter at the point where the particle size accumulates in order of smallest to X% (where % is calculated based on number, volume, or weight) is Y. For example, D(10) represents the particle diameter at the point where the particle size of the drug accumulates in order of smallest to 10%, D(50) represents the particle diameter at the point where the particle size of the drug accumulates in order of smallest to 50%, and D(90) represents the particle diameter at the point where the particle size of the drug accumulates in order of smallest to 90%.
[0053] Whether the particle size distribution D(X) represents a percentage of the total accumulated particles based on number, volume, or weight depends on the method used to measure the particle size distribution. Methods for measuring particle size distribution and the types of percentages associated therewith are known in the art. For example, when measuring particle size distribution by the well-known laser diffraction method, the X value in D(X) represents the percentage calculated by the volume average. Those skilled in the art are well aware that the results of particle size distribution measurements obtained by a particular method may correlate with those obtained from other techniques based on experience from conventional experiments. For example, the laser diffraction method provides a volume-averaged particle size in response to the volume of the particles, which corresponds to the weight-averaged particle size when the density is constant.
[0054] In the present invention, the measurement of the particle size distribution of drug particles can be performed using a commercially available device based on the laser diffraction and scattering method according to Mie theory. For example, the measurement is performed using a commercially available device such as the Mastersizer laser diffraction device from Malvern Instruments. This device obtains the particle diameter distribution by irradiating particles with a helium-neon laser beam and a blue light-emitting diode, causing scattering to occur and a light scattering pattern to appear on a detector, and interpreting this light scattering pattern according to Mie theory. Either a dry or wet method may be used for the measurement.
[0055] For reference, in a specific embodiment of the present invention, the particle size of the drug was measured by the volume average particle size by laser diffraction.
[0056] In a specific embodiment of the present invention, the inabogliflozin may be included in an amount of less than 1 part by weight per 100 parts by weight of the total pharmaceutical composition.
[0057] The appropriate once-daily dosage of inabogliflozin identified during clinical trials is 0.1 mg to 0.5 mg, and when the above pharmaceutical composition is formulated into a unit dosage form, the content of the active ingredient in the pharmaceutical composition may be 0.1 to 0.5 mg.
[0058] The pharmaceutical composition according to the present invention includes pharmaceutically acceptable additives in addition to the active ingredient inabogliflozin.
[0059] The pharmaceutical composition of the present invention includes excipients, disintegrants, and binders as additives.
[0060] Examples of excipients include lactose (including hydrates), dextrin, mannitol, sorbitol, starch, microcrystalline cellulose [e.g., Celphere™], silicified microcrystalline cellulose [e.g., Prosolv™], calcium phosphate hydrate, anhydrous calcium phosphate, calcium carbonate, sugars, or mixtures thereof. In embodiments of the present invention, a preferred excipient is microcrystalline cellulose.
[0061] Examples of disintegrants include crospovidone, sodium croscarmellose, sodium starch glycolate, and low-substituted hydroxypropylcellulose. In a specific embodiment of the present invention, a preferred excipient is sodium croscarmellose.
[0062] Examples of binders include polyvinylpyrrolidone, povidone, gelatin, starch, sucrose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylalkylcellulose (e.g., hydroxypropylmethylcellulose), and mixtures thereof. In a specific embodiment of the present invention, a preferred binder is hydroxypropylcellulose.
[0063] Examples of other additives include lubricants and coloring agents.
[0064] The above lubricant comprises stearic acid, stearate (e.g., magnesium stearate), hard anhydrous silica, talc, corn starch, carnauba wax, magnesium silicate, synthetic aluminum silicate, hardened oil, white wax, titanium oxide, microcrystalline cellulose, macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, and mixtures thereof.
[0065] In a specific embodiment of the present invention, the excipient may be included in an amount of 80 to 95 parts by weight relative to 100 parts by weight of the total pharmaceutical composition.
[0066] In a specific embodiment of the present invention, the disintegrant may be included in an amount of 2 to 8 parts by weight relative to 100 parts by weight of the total pharmaceutical composition. If the amount of disintegrant is less than 2 parts by weight relative to 100 parts by weight of the total pharmaceutical composition, the initial disintegration power is low and the dissolution rate may be delayed, which may affect the Cmax in the body. In addition, if the amount exceeds 8 parts by weight relative to 100 parts by weight of the total pharmaceutical composition, the amount of disintegrant in the post-mixing portion increases, so the overall flowability of the granules may decrease.
[0067] In a specific embodiment of the present invention, the binder may be included in an amount of 3 to 10 parts by weight per 100 parts by weight of the total pharmaceutical composition. If the binder is less than 3 parts by weight per 100 parts by weight of the total pharmaceutical composition, it may be difficult to form and maintain suitable dry granules, which may affect the maintenance of homogeneous dispersion of the main ingredient and the granule flowability due to the generation of fine particles. In addition, if it exceeds 10 parts by weight per 100 parts by weight of the total pharmaceutical composition, granules with strong binding force are formed, which affects the solubility of the granule particles that disintegrate initially upon dissolution, and this may also affect the Cmax in the body.
[0068] The pharmaceutical composition according to the present invention may be an immediate-release formulation.
[0069] In one embodiment of the present invention, the pharmaceutical composition may have a dissolution rate of 50% or more, preferably 60% or more, of the total content of the active ingredient after 5 minutes.
[0070] In one embodiment of the present invention, the pharmaceutical composition may have a dissolution rate of 80% or more of the total content of the active ingredient after 15 minutes, preferably 80% or more.
[0071] In one embodiment of the present invention, the pharmaceutical composition may have a dissolution rate of 85% or more, preferably 90% or more, of the total content of the active ingredient after 30 minutes.
[0072] Since the dissolution rate of the active ingredient in a pharmaceutical composition affects the peak blood concentration (Cmax) and the area under the blood concentration-time curve (AUC) upon drug administration, conversely, it is important to adjust the dissolution rate of the pharmaceutical composition to achieve appropriate Cmax and AUC. As Inabogliflozin has a Tmax of 1 to 2 hours, the drug absorption rate in the stomach is considered important. The above dissolution rate was measured under conditions 1.2 of the dissolution solution by the Korean Pharmacopoeia Dissolution Test Method 2 (Paddle Method). Specific conditions may be referenced in the experimental examples below.
[0073] The present invention also
[0074] The present invention provides a pharmaceutical composition comprising a pre-mixed granule containing inabogliflozin or a pharmaceutically acceptable salt thereof and a post-mixed granule containing a mixed portion.
[0075] The inventors confirmed that, during the formulation research of inabogliflozin, preparing granules and formulating them into tablets or the like is advantageous in terms of drug content uniformity and formulation uniformity.
[0076] In the above pharmaceutical composition, the granules are prepared by mixing the pre-mixed granules and the post-mixed part.
[0077] The above-mentioned premixed granules may include inabogliflozin or its pharmaceutically acceptable salt, excipients, binders, and lubricants.
[0078] In addition, the above-mentioned post-mixing part may include an excipient, a disintegrant, and a lubricant.
[0079] The descriptions of excipients, binders, disintegrants, lubricants, etc. are identical to those described above, so they are omitted to avoid duplication.
[0080] In a specific embodiment of the present invention, the pre-mixed granules and the post-mixed part may each include an excipient. More specifically, the pre-mixed granules and the post-mixed part may each include microcrystalline cellulose as an excipient.
[0081] According to the following examples, it was found that the microcrystalline cellulose included in the pre-mixed granules and post-mixed parts affects the uniformity of the drug content depending on its particle size and bulk density.
[0082] In a specific embodiment of the present invention, the particle size of the microcrystalline cellulose in the premixed granules may be 130 µm or less, preferably 60 to 130 µm. The bulk density of the microcrystalline cellulose in the premixed granules may be 0.26 to 0.33. When the particle size and bulk density of the microcrystalline cellulose in the premixed granules are under the above conditions, a formulation with a low deviation (SD) in content uniformity can be secured. When the particle size of the microcrystalline cellulose in the premixed granules is 130 µm or less, the content uniformity of the premixed granules, the content uniformity of the final granules, and the formulation all showed good levels, and the Carr's index value, which indicates the physical properties of the final granules, was also good, confirming that the flowability of the formulation was also excellent. On the other hand, when the particle size of microcrystalline cellulose in the premixed granules exceeded 130 µm, both the content uniformity of the premixed granules and the content uniformity of the final granules showed large deviations and were unsuitable, and the formulation uniformity was also found to be poor.
[0083] Meanwhile, the particle size of the microcrystalline cellulose in the post-mixing section may be 130 µm or more, preferably 130 to 250 µm. The bulk density of the excipient in the post-mixing section may be 0.28 to 0.37. When the particle size of the microcrystalline cellulose in the post-mixing section is less than 130 µm, it was confirmed that the Carr's index value, which indicates the physical properties of the final granules, was not appropriate and the granule flowability became weak.
[0084] When comparing the microcrystalline cellulose in the pre-mixed granules and the microcrystalline cellulose in the post-mixed section relatively, it was found that, unlike the microcrystalline cellulose contained in the pre-mixed granules which is desirable to have a small particle size, the microcrystalline cellulose in the post-mixed section which is desirable to have a relatively larger particle size compared to the microcrystalline cellulose contained in the pre-mixed granules.
[0085] According to the following examples, it was confirmed that not only the particle size of microcrystalline cellulose in the pre-mixed granules and microcrystalline cellulose in the post-mixed portion, but also the weight ratio of excipients in the pre-mixed granules and excipients in the post-mixed portion affects the uniformity of the drug content.
[0086] In a specific embodiment of the present invention, the weight ratio of the excipient in the pre-mixed granules and the excipient in the post-mixed portion may be 4:1 to 1:1. It was found that as the proportion of microcrystalline cellulose in the post-mixed portion increases, the flowability of the granules improves, while the variation in content increases, so it is desirable to match the weight ratio within the appropriate range.
[0087] Meanwhile, in the pharmaceutical composition according to the present invention, the binder may be one or more selected from the group consisting of hydroxypropylcellulose, povidone, copovidone, and hypromellose.
[0088] In one embodiment of the present invention, the binder is hydroxypropylcellulose and may have a weight-average molecular weight of less than 200,000. If hydroxypropylcellulose with a weight-average molecular weight of 200,000 or more is used, both the 5-minute dissolution rate and the 30-minute dissolution rate are low, which is undesirable in terms of bioavailability.
[0089] Meanwhile, regarding Carr's index used as a measure of flowability in formulation, it is preferable that the Carr's index of the granules be 21 to 25.
[0090] Although not limited thereto, the granules in the pharmaceutical composition of the present invention may be dry granules. In other embodiments, the granules may be wet granules.
[0091] In the present invention, the pharmaceutical composition may have a formulation for oral administration, such as a tablet or capsule. In one embodiment of the present invention, the pharmaceutical composition may have a tablet formulation.
[0092] In a preferred embodiment, the pharmaceutical composition may contain inabogliflozin in a dose of 0.3 mg to 0.5 mg.
[0093] The pharmaceutical composition according to the present invention may be administered orally once a day, but is not limited thereto.
[0094] The pharmaceutical composition of the present invention containing inabogliflozin as an active ingredient can be usefully used for the prevention or treatment of metabolic dysfunction-associated steatotic liver disease (MASLD).
[0095] Figure 1 shows the results of an integrated analysis of data from three randomized, double-blind, Phase 3 clinical trials conducted over 24 weeks, illustrating the change in the proportion of patients exceeding the cutoff criteria for the Hepatic Steatosis Index (HSI) and Framingham Steatosis Index (FSI) measured before drug administration and 24 weeks after administration.
[0096] Figure 2 illustrates the results of the in vivo efficacy evaluation of inabogliflozin using a MASLD animal model. Specifically, Figure 2a shows the protocol for the evaluation of the MASLD inhibitory effect of inabogliflozin using STAM mice, and Figure 2b shows a graph of the NAFLD (non-alcoholic fatty liver disease) activity scores of the negative control group and the inabogliflozin administration group.
[0097] One or more specific examples are described in more detail below through embodiments. However, these embodiments are intended to illustrate one or more specific examples and the scope of the present invention is not limited to these embodiments.
[0098]
[0099] [Example]
[0100] Example 1: Evaluation of MASLD improvement effect in patients with type 2 diabetes
[0101] In this example, a series of analyses were performed to evaluate the effect of inabogliflozin administration on liver fat accumulation and fibrosis indicators in patients with type 2 diabetes mellitus accompanied by MASLD (Metabolic dysfunction-associated steatotic liver disease).
[0102]
[0103] The analysis was performed by integrating data from three randomized, double-blind, Phase 3 clinical trials conducted over 24 weeks.
[0104]
[0105] Table 1 shows demographic information, blood biochemical indicators, and metabolic values such as body weight and BMI at baseline for all patients for whom this analysis was performed.
[0106] Placebo-controlled clinical trial Active control drug clinical trial Enavogliflozin 0.3 mg (n=82) Placebo (n=79) p-value Enavogliflozin 0.3 mg (n=214) Dapagliflozin 10 mg (n=213) p-value Male, n (%) 47 (57.32) 35 (44.3) 0.09 87 119 (55.61) 113 (53.05) 0.59 60 Age, years 59.73 (11.44) 58.87 (11.16) 0.64 66 58.62 (10.53) 59.32 (10.25) 0.51 38 HbA1c, % 7.64 (0.66) 7.72 (0.63) 0.24 137.77 (0.79) 7.77 (0.78)0.9722FPG, mg / dL141.00 (24.10)141.47 (23.51)0.7518142.01 (27.46)144.24 (30.88)0.8531Weight, kg68.77 (12.55)69.14 (13.66)0.854969.67 (11.64)68.61 (11.66)0.3472BMI, kg / m 2 25.60 (3.07)26.32 (3.55)0.166626.07 (3.51)25.83 (3.21)0.7189Adiponectin, mg / L7.79 (4.94)8.31 (4.79) 0.31066.55 (4.44)6.45 (3.77)0.6910Total Cholesterol, mg / dL † 161.42 (36.14)165.53 (35.08)0.3055141.94 (29.86)141.31 (32.15)0.8854LDL Cholesterol, mg / dL † 95.47 (33.86)99.01 (33.01)0.409078.07 (27.49)76.88 (28.09)0.7161HDL Cholesterol, mg / dL † 51.92 (10.64)49.20 (11.90)0.065548.21 (10.58)47.20 (10.15)0.3035Triglyceride, mg / dL †117.44 (49.60)137.88 (75.62)0.1715120.40 (71.68)132.67 (87.14)0.1546eGFR, ml / min / 1.73m 2 89.31 (17.79)88.87 (21.32)0.886089.32 (18.61)92.08 (19.58)0.1586C-peptide, nmol / L0.75 (0.30)0.76 (0.30)0.84170.73 (0.27)0.71 (0.22)0.8508HOMA-IR3.47 (2.88)3.61 (2.57)0.53713.15 (2.69)3.28 (2.19)0.3061HOMA-beta46.40 (33.07)51.08 (45.47)0.691144.07 (31.48)42.14 (26.38)0.6947SBP, mmHg † 127.85 (13.39)129.47 (12.31)0.4376128.49 (13.17)125.40 (12.87)0.0161DBP, mmHg † 76.23 (8.12)76.80 (8.61)0.677076.80 (9.45)74.73 (9.46)0.0262UACR, g / kg28.20 (68.67)53.92 (190.18)0.276943.18 (145.36)44.24 (148.48) ‡ 0.8542UGCR, g / g1.42 (7.89)0.18 (0.25)0.18551.08 (6.35)1.66 (7.43) ‡ 0.5392
[0107] Specifically, for a total of three clinical trials (corresponding to 301, 302, and 303, respectively) listed in Table 2 below, non-invasive indicators reflecting fatty liver or liver fibrosis were analyzed, and each trial was composed as follows:
[0108]
[0109] (1) Test subjects
[0110] A total of 555 adult patients diagnosed with type 2 diabetes were included in this study. For placebo-controlled trials, the analysis was performed based on the FAS set (analysis of subjects who received the investigational drug at least once after randomization), and for active comparator-controlled trials, the analysis was performed based on the PPS set (subjects from the FAS analysis group who completed the 24-week treatment period without serious protocol violations).
[0111] Accordingly, this analysis was performed only on patients who met both the primary and secondary endpoint criteria (FAS1, FAS2) from the entire analysis group (FAS), or patients who met both the primary and secondary endpoint criteria (PPS1, PPS2) from the protocol compliance group (PPS) (total n=555).
[0112] 1) Placebo-controlled clinical trial [301 data set]
[0113] Enblo administration group n=75
[0114] Placebo group n=71
[0115] 2) Active control drug clinical trial [302+303 data set]
[0116] Enblo administration group n=205
[0117] Active control drug administration group n=204
[0118]
[0119] (2) Composition of test group and administration method
[0120] Classification Administration Information 301 Enblo Group: Comparison of Inavogliflozin 0.3 mg Monotherapy Group: Placebo Monotherapy (Placebo is not a dose) 302 Enblo Group: Comparison of Inavogliflozin 0.3 mg + Metformin 1000 mg Dual Combination Therapy Group: Dapagliflozin 10 mg + Metformin 1000 mg Dual Combination Therapy 303 Enblo Group: Comparison of Inavogliflozin 0.3 mg + Metformin 1000 mg + Gemiglipin 50 mg Triple Combination Therapy Group: Dapagliflozin 10 mg + Metformin 1000 mg + Gemiglipin 50 mg Triple Combination Therapy
[0121] Inabogliflozin (0.3 mg / day) was administered to 75 patients in a monotherapy clinical trial (301) conducted as a placebo-controlled clinical trial (placebo group: n = 71), and to 205 patients in a two-drug combination therapy clinical trial (302) and a three-drug combination therapy clinical trial (303) conducted as active drug clinical trials (active drug group; n = 204).
[0122]
[0123] (3) Analysis time point and evaluation variables
[0124] Blood biochemical indicators and metabolic values such as body weight and BMI were measured at baseline and 24 weeks after administration, and MASLD-related indicators such as HSI, FSI, and NFS were calculated based on the above data.
[0125]
[0126] The assessment of the likelihood of hepatic steatosis was performed using the Hepatic Steatosis Index (HSI) and the Framingham Steatosis Index (FSI). Patients assessed as having hepatic steatosis at baseline (HSI > 36 or FSI ≥ -1.2) subsequently had changes in the degree of liver fibrosis evaluated using non-invasive serological markers such as the Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS).
[0127]
[0128] The evaluation criteria are as follows:
[0129] - MASLD patient ratio (ratio exceeding cut-off criteria)
[0130] - Change in absolute value of MASLD-related indicators
[0131] - Statistical significance (p-value) and differences between groups
[0132]
[0133] (4) Statistical analysis
[0134] The significance of within-group changes in each indicator was evaluated using paired t-tests or Wilcoxon tests, and the difference in effect between the inabogliflozin group and the control group was evaluated through ANCOVA analysis adjusted for covariates. Statistical significance was determined based on a p-value < 0.05.
[0135]
[0136] Example 1-1: Changes in the proportion of MASLD patients according to HSI and FSI
[0137] In this embodiment, changes in the proportion of patients with MASLD were evaluated based on the Hepatic Steatosis Index (HSI) and Framingham Steatosis Index (FSI), which are non-invasive indicators reflecting MASLD status. MASLD was defined as HSI > 36 or FSI ≥ -1.2, and the evaluation points were before administration (baseline) and at 24 weeks (week 24).
[0138] 301 (monotherapy)302 + 303 Integrated analysis Enavogliflozin 0.3mg (n=75)Placebo (n=71)Enavogliflozin 0.3mg (n=205)Dapagliflozin 10mg (n=204)N (%)baselineweek 24baselineweek 24baselineweek 24baselineweek 24HSI(cut off >36)36(48.00)12(16)37(52.11)34(50)101(49.51)62(30.24)104(50.98)65(3) 1.86)p<0.0001p=0.6171p<0.0001p<0.0001p<0.0001p=0.7235FSI(Framingham steatosis index)31(41.33)12(16)34(47.89)29(42.65)93(45.59)49(23.9)96(47.06)54(26.47)p<0.0001p=0.3171p<0.001p<0.001p=0.0004p=0.5497
[0139] ※ Note HSI= 8 × ALT / AST ratio + BMI (+2, if adiabetes; +2, if female),cut off: >36,FSI= 7.981 + 0.011 × Age (years) 0.146 × Gender (Female = 1, Male = 0) + 0.173 × BMI (kg / m2) + 0.007 × Triglycerides (mg / dL) + 0.593 × Hypertension (Yes = 1, No = 0) + 0.789 × Diabetes (Yes = 1, No = 0) + 1.1 × ALT:AST ratio ≥ 1.33 (Yes = 1, No = 0).cuf off >=-1.2
[0140] As can be seen in Table 3 and Figure 1 above, in the inabogliflozin treatment group, the proportion of patients with MASLD defined by HSI and FSI criteria was significantly reduced after 24 weeks of treatment.
[0141] In a monotherapy clinical trial (301), when inabogliflozin monotherapy was administered, the proportion of patients with MASLD decreased significantly from 48.00% to 16.00% based on HSI and from 41.33% to 16.00% based on FSI, showing a statistically significant difference compared to the placebo group (HSI: p<0.0001, FSI: p=0.0004).
[0142] In the combined analysis of the clinical trials of two-drug combination therapy (302) and three-drug combination therapy (303), the inabogliflozin group showed a significant decrease from baseline, with the proportion of patients with MASLD based on HSI decreasing from 49.51% to 30.24% and based on FSI decreasing from 45.59% to 23.90%. There was no statistically significant difference compared to dapagliflozin, with p=0.7235 based on HSI and p=0.5497 based on FSI.
[0143]
[0144] Example 1-2: Evaluation of MASLD Improvement Effect by Analysis of Changes in HSI Score
[0145] In this example, the change in the HSI score, which can quantitatively evaluate the degree of fat accumulation in the liver, was analyzed. HSI is a continuous indicator, and the mean change between before administration (baseline) and after 24 weeks (week 24), along with the adjusted mean difference, 95% confidence interval, and p-value, were calculated.
[0146] HSI (Hepatic steatosis index)301 (monotherapy)302 + 303 Integrated analysisEnavogliflozin 0.3mg (n=36)Placebo (n=37)Enavogliflozin 0.3mg (n=101)Dapagliflozin10mg (n=104)BaselineMean(SD)39.70 (2.39)40.42 (3.18)41.24 (4.10)40.72 (3.82)Median39.2239.9440.5140.13Min, Max36.14, 44.6536.84, 50.0436.03, 53.7736.06, 54.47Change from baseline at Week 24Mean(SD)-4.37 (2.34)-0.79 (3.58)-4.21 (2.94)-3.15 (3.75)Median-4.36-1.08-3.89-2.99Min, Max-7.73, 2.03-11.29, 5.77-14.42, 2.45-14.79, 13.18P-value [1]<.00010.1918<.0001<.0001ANCOVA ResultLS Mean(SE)-4.54 (0.55)-0.82 (0.57)-4.51 (0.35)-3.49 (0.34)LS Mean Difference [95% CI]-3.72[-5.17,-2.27]-1.02[-1.91,-0.12]P-value [2]<.00010.0257
[0147] ※ Reference HSI = 8 × ALT / AST ratio + BMI (+2, if diabetes; +2, if female), cut off: >36 (fatty liver)[1] Testing for change within-treatment group (Paired t-test or Wilcoxon signed rank test).
[0148] [2] Testing for differences between Enavogliflozin and Dapagliflozin using ANCOVA with covariates including baseline value and stratification factors such as the regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8% or ≥ 8%].
[0149]
[0150] As a result of the HSI score analysis, the HSI score in the inabogliflozin group decreased statistically significantly after 24 weeks. In the inabogliflozin monotherapy clinical trial (301), the adjusted mean difference in reduction compared to placebo was -3.72 points (95% CI: -5.17, -2.27, p<0.0001), and in the combined analysis of the two-drug combination therapy clinical trial (302) and the triple combination therapy clinical trial (303), the adjusted mean difference compared to the dapagliflozin group was -1.02 points (95% CI: -1.91, -0.12, p=0.0257), confirming a statistically significant improvement effect. This demonstrates that inabogliflozin quantitatively and significantly improves hepatic fat accumulation in MASLD patients.
[0151]
[0152] Examples 1-3: Evaluation of MASLD Improvement Effect by Analysis of Changes in FSI Score
[0153] In this example, the effect of administering inabogliflozin on the FSI (Framingham Steatosis Index) score in patients with MASLD was evaluated. The FSI is a continuous index reflecting the risk of hepatic fat accumulation, and the mean change between baseline and 24 weeks later, along with the adjusted mean difference, 95% confidence interval, and p-value, were calculated.
[0154] FSI (Framingham steatosis index)301 (monotherapy)302 + 303 Integrated analysisEnavogliflozin 0.3mg (n=31)Placebo (n=34)Enavogliflozin 0.3mg (n=93)Dapagliflozin10mg (n=96)BaselineMean(SD)-0.32 (0.62)-0.25 (0.82)-0.10 (0.93)-0.14 (0.83)Median-0.46-0.55-0.42-0.31Min, Max-1.20, 1.48-1.18, 2.89-1.19, 3.18-1.20, 2.55Change from baseline at Week 24Mean(SD)-1.17 (0.97)0.03 (1.46)-1.12(0.97)-1.03 (1.00)Median-1.24-0.25-1.05-1.09Min, Max-2.34, 1.39-2.86, 4.61-3.69, 1.51-3.26, 1.83P-value [3]<.00010.4247<.0001<.0001ANCOVA ResultLS Mean(SE)-1.23 (0.24)-0.07 (0.24)-1.13 (0.10)-1.06 (0.10)LS Mean Difference [95% CI]-1.16[-1.80,-0.52]-0.07[-0.32,0.19]P-value [1,2]0.00060.6195
[0155] ※ Note FSI = 7.981 + 0.011 × Age (years) 0.146 × Gender (Female = 1, Male = 0) + 0.173 × BMI (kg / m2) + 0.007 × Triglycerides (mg / dL) + 0.593 × Hypertension (Yes = 1, No = 0) + 0.789 × Diabetes (Yes = 1, No = 0) + 1.1 × ALT:AST ratio ≥ 1.33 (Yes = 1, No = 0).cuf off >=-1.2[1] Testing for change within-treatment group (Paired t-test or Wilcoxon signed rank test).
[0156] [2] Testing for differences between Enavogliflozin and Dapagliflozin using ANCOVA with covariates including baseline value and stratification factors such as the regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8% or ≥ 8%].
[0157]
[0158] In the clinical trial of inabogliflozin monotherapy (301), the inabogliflozin group showed a decrease in FSI score of -1.17 points compared to baseline, and the adjusted mean difference was -1.16 points (95% CI: -1.80, -0.52, p=0.0006), showing a statistically significant improvement effect compared to the placebo group.
[0159] On the other hand, in the combined analysis of the 2-drug combination therapy clinical trial (302) and the 3-drug combination therapy clinical trial (303), the adjusted mean difference of the inabogliflozin group compared to the dapagliflozin group was -0.07 points (95% CI: -0.32, 0.19, p=0.6195), and no statistically significant difference was observed.
[0160] These results show that inabogliflozin can significantly reduce the risk of FSI-based fatty liver in patients with MASLD.
[0161]
[0162] Examples 1-4: Evaluation of changes in the proportion of MASLD patients according to fibrosis risk indicators (NFS, FNI) (subjects satisfying the HSI score)
[0163] In this example, based on subjects satisfying the HSI score at the baseline of Example 1-1, the effect of administering inabogliflozin on the proportion of high-risk patients according to fibrosis-related indicators (NFS, FNI) in MASLD patients was evaluated. Changes in the proportion of high-risk patients following 24 weeks of treatment were observed by applying cutoff criteria for each indicator.
[0164] 301 (monotherapy)302 + 303 Integrated analysisEnavogliflozin 0.3mgPlaceboEnavogliflozin 0.3mgDapagliflozin 10mgN (%)baselineweek 24baselineweek 24baselineweek 24baselineweek 24NFS(NAFLDfibrosis score)36(100)35(97.22)35(94.59)35(97.22)94(93.07)91(90.1)102(98.08) )97(93.27)p>.9999p>.9999p=0.4531p=0.1250p>.9999p=0.4106FNI(Fibrotic NASH Index)12(33.33)6(16.67)16(43.24)10(27.78)47(46.53)11(10.89)59( 56.73)19(18.27)p=0.1460p=0.1460p<0.0001p<0.0001p=0.2568p=0.1351
[0165] ※ Note: NFS = 1.675 + 0.037 × age (yrs) + 0.094 × BMI (kg / m²) 2)+1.13×IFG / type 2 diabetes (yes=1, no=0)+0.99×AST:ALT ratio-0.013×platelets (10 9 / L) -0.66×albumin (gr / dL)cuf off > 0.676,FNI= (e(-10.33+2.54×ln(AST)+3.86×ln(HbA1c)-1.66×ln(HDL))) / (1+e(-10.33+2.54×ln(AST)+3.86×ln(HbA1c)-1.66×ln(HDL))),cutoff >=0.33
[0166] According to the results of the clinical trial (301) of inabogliflozin monotherapy, no significant difference was observed between the groups in terms of NFS score cutoff (>0.676) and FNI score cutoff (>0.33).
[0167] According to the results of the combined analysis of the two-drug combination therapy clinical trial (302) and the three-drug combination therapy clinical trial (303), there was no significant difference according to the NFS criteria, but the within-group change according to the FNI score cutoff (≥0.33) criteria was statistically significant (p<0.0001). These results suggest that inabogliflozin can significantly reduce the proportion of the FNI-based fibrosis risk group in MASLD patients.
[0168]
[0169] Examples 1-5. Placebo-controlled study - Change in MASLD score (NFS)
[0170] Among the subjects who participated in the inabogliflozin monotherapy clinical trial (301), the two-drug combination therapy clinical trial (302), and the three-drug combination therapy clinical trial (303), the average change in NFS score was analyzed for the patient group with an HSI score greater than 36.
[0171] In particular, this example shows the results of a subgroup analysis performed on a patient group that satisfied the NFS score cutoff (>0.676) among patients who reached the 24-week mark in Examples 1-4.
[0172] NFS(NAFLD fibrosis score)301(단독요법)302 + 303 통합분석Enavogliflozin 0.3mg(n=35)Placebo(n=35)Enavogliflozin 0.3mg(n=91)Dapagliflozin10mg(n=97)BaselineMean(SD)2.04 (0.57)1.86 (0.72)2.12 (0.61)1.93 (0.55)Median1.981.972.081.85Min, Max0.99,3.28-0.12,3.300.25,3.810.57,3.75Change from baseline at Week 24Mean(SD)-0.12 (0.48)0.10 (0.31)-0.05 (0.38)-0.10 (0.42)Median0.040.02-0.04-0.03Min, Max-1.46, 0.44-0.37, 1.17-1.25, 0.76-1.58, 0.79P-value [1]0.88530.10210.32710.1357ANCOVA ResultLS Mean(SE)-0.09 (0.07)0.10 (0.07)-0.03 (0.04)-0.12 (0.04)LS Mean Difference [95% CI]-0.19[-0.37, 0.00]0.09[-0.02, 0.21]P-value [2]0.04520.1206
[0173] ※ 참고:NFS= 1.675+0.037××BMI kg / m 2 )+1.13×IFG / type 2 diabetes (yes=1, no=0)+0.99×AST:ALT ratio-0.013×plateles (10 9 / L)-0.66×albumin (gr / dL)cuf off > 0.676[1] Testing for change within-treatment group (Paired t-test or Wilcoxon signed rank test).
[0174] [2] Testing for differences between Enavogliflozin and Dapagliflozin using ANCOVA with covariates including baseline value and stratification factors such as the regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8% or ≥ 8%].
[0175]
[0176] The inabogliflozin 0.3 mg group showed a significant improvement in the NFS score at 24 weeks compared to the placebo group, with a significant LS Mean Difference of -0.19 [95% CI: -0.37, 0.00], p=0.0452. In contrast, there was no significant difference when compared to the dapagliflozin 10 mg group (p=0.1206).
[0177]
[0178] Examples 1-6. Placebo-controlled study - Change in MASLD score (FNI)
[0179] Among the subjects who participated in the inabogliflozin monotherapy clinical trial (301), the two-drug combination therapy clinical trial (302), and the three-drug combination therapy clinical trial (303), the average change in FNI score was analyzed for the patient group with an HSI score greater than 36.
[0180] In particular, this example shows the results of a subgroup analysis performed on a patient group that satisfied the FNI score cutoff (≥0.33) among patients who reached the 24-week mark in Examples 1-4.
[0181] FNI(NAFLD fibrosis score)301(단독요법)302 + 303통합분석Enavogliflozin 0.3mg(n=6)Placebo(n=10)Enavogliflozin 0.3mg(n=11)Dapagliflozin10mg(n=19)BaselineMean(SD)0.48 (0.26)0.48 (0.23)0.79 (0.18)0.65 (0.22)Median0.460.410.820.73Min, Max0.23,0.830.25,0.880.45,0.980.26,0.96Change from baseline at Week 24Mean(SD)0.00 (0.33)0.13 (0.10)-0.20 (0.20)-0.09 (0.25)Median-0.060.12-0.13-0.07Min, Max-0.31,0.53-0.07,0.32-0.48,0.10-0.41,0.43P-value [1]0.97730.00360.00770.1445ANCOVA ResultLS Mean(SE)0.06 (0.09)0.10 (0.06)-0.17 (0.07)-0.15 (0.05)LS Mean Difference [95% CI]-0.05[-0.26,0.17]-0.02[-0.18,0.13]P-value [2]0.65190.7447
[0182] ※ 참고:FNI= (e(-10.33+2.54×ln(AST)+3.86×ln(HbA1c)-1.66×ln(HDL))) / (1+e(-10.33+2.54×ln(AST)+3.86×ln(HbA1c)-1.66×ln(HDL))), cutoff>=0.33[1] Testing for change within-treatment group (Paired t-test or Wilcoxon signed rank test).
[0183] [2] Testing for differences between Enavogliflozin and Dapagliflozin using ANCOVA with covariates including baseline value and stratification factors such as the regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8% or ≥ 8%].
[0184]
[0185] No significant difference was observed between the inabogliflozin 0.3 mg group and the placebo group at the FNI score cutoff (≥0.33) at 24 weeks. On the other hand, in the comparison with the dapagliflozin 10 mg group, the within-group change at the FNI score cutoff (≥0.33) was statistically significant (p=0.0077).
[0186]
[0187] Example 2: Change in HSI (Hepatic Steatosis Index) (302 patient group)
[0188] This example is the result of analyzing the change in Hepatic Steatosis Index (HSI) score between the inabogliflozin 0.3 mg + metformin combination group and the dapagliflozin 10 mg + metformin combination group, based on the 302 clinical trial groups of Example 1. The HSI criteria were analyzed by dividing them into two cutoff criteria (>36 or >30), and the score change after 24 weeks from baseline and the mean difference between treatment groups (ANCOVA) were statistically tested for each group.
[0189] Dataset302(PPS)Variable-SCORE-Enavogliflozin 0.3 mgDapagliflozin 10 mgHSI (Case1)cutoff >36Week 24 n5045Mean(SD)36.23 (4.02)38.04 (5.07)Median36.3336.77Min, Max29.49,45.2627.78,50.02Change from baseline at Week 24n5045Mean(SD)-5.12 (3.05)-3.49 (3.98)Median-4.70-2.81Min, Max-14.42,0.19-14.79,3.90P-value [1]<.0001<.0001Test of P-value [1]Paired t-testPaired t-testANCOVA ResultLS Mean(SE)-5.30 (0.52)-3.53 (0.52)LS Mean Difference-1.7895% CI for Difference[-3.19,-0.37]P-value [2]0.0141HSI (Case2)cutoff >30Week 24 n8683Mean(SD)34.09 (4.21)34.95 (5.67)Median33.3534.2Min, Max26.92,45.2624.71,50.02Change from baseline at Week 24 n8683Mean(SD)-3.99 (2.95)-2.75 (3.93)Median-3.82-2.64Min, Max-14.42,1.11-14.79,16.42P-value [1]<.0001<.0001Test of P-value [1]Wilcoxon signed rank testWilcoxon signed rank testANCOVA ResultLS Mean(SE)-3.96 (0.36)-2.82 (0.37)LS Mean Difference-1.1495% CI for Difference[-2.12,-0.15]P-value [2]0.0236
[0190] [1] Testing for change within-treatment group (Paired t-test or Wilcoxon signed rank test).[2] Testing for differences between Enavogliflozin and Dapagliflozin using ANCOVA with covariates including baseline value and stratification factors such as the regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8% or ≥ 8%].
[0191]
[0192] HSI Criteria Case 1 (cutoff > 36)
[0193] HSI scores were evaluated in the inabogliflozin 0.3 mg + metformin combination therapy patient group (n=50) and the dapagliflozin 10 mg + metformin combination therapy patient group (n=45) who satisfied HSI > 36 at baseline.
[0194] The average HSI score of the inabogliflozin group at week 24 was 36.23 ± 4.02, and the average change from baseline was -5.12 ± 3.05.
[0195] For the dapagliflozin group, the mean HSI score at week 24 was 38.04 ± 5.07, and the mean change from baseline was -3.49 ± 3.98.
[0196] A paired t-test was used to statistically test for within-group changes, and a statistically significant decrease from baseline was confirmed in both groups (p < 0.0001).
[0197] ANCOVA analysis showed that the mean change in LS for the inabogliflozin group was -5.30 ± 0.52 and for the dapagliflozin group was -3.53 ± 0.52, and the mean difference in LS between the two groups was -1.78 (95% CI: -3.19, -0.37), which was statistically significant (p = 0.0141).
[0198]
[0199] HSI Criteria Case 2 (cutoff > 30)
[0200] HSI scores were evaluated in the same manner as above for the inabogliflozin 0.3 mg + metformin combination therapy patient group (n=86) and the dapagliflozin 10 mg + metformin combination therapy patient group (n=83) who satisfied HSI > 30 at baseline.
[0201] The mean HSI score at week 24 for the inabogliflozin group was 34.09 ± 4.21, with a mean change from baseline of -3.99 ± 2.95, while for the dapagliflozin group it was 34.95 ± 5.67 and -2.75 ± 3.93, respectively.
[0202] The Wilcoxon signed-rank test was used to statistically test for within-group change, and a significant decrease from baseline was confirmed in both groups (p < 0.0001).
[0203] ANCOVA results showed that the mean change in LS for the inabogliflozin group was -3.96 ± 0.36 and for the dapagliflozin group was -2.82 ± 0.37, and the mean difference in LS between the two groups was -1.14 (95% CI: -2.12, -0.15), which was statistically significant (p = 0.0236).
[0204] From the above results, it was confirmed that co-administering inabogliflozin 0.3 mg with metformin can significantly improve the HSI scores of MASLD patients compared to co-administering dapagliflozin 10 mg. In particular, statistically significant improvement effects were observed in both subgroup analyses applying two types of HSI criteria (cutoff >36 and >30).
[0205]
[0206] Example 3: In vivo effect of inabogliflozin on improving MASLD using a STAM mouse model
[0207] In this example, the effect of inabogliflozin on improving liver pathology was evaluated using the STAM (Streptozotocin-and-High-Fat-Diet-induced NASH) mouse model, an animal model of metabolic disorder-associated fatty liver (MASLD) accompanied by diabetes.
[0208] MASLD pathology was induced in male C57BL / 6J mice by administering a single dose of Streptozotocin (STZ) followed by feeding a high-fat diet (HFD) for 5 weeks (Fig. 2a). Starting from the 3rd week after the initiation of HFD feeding, inabogliflozin was orally administered once daily for 3 weeks at concentrations of 0.3, 3, and 30 mg / kg, and obeticholic acid (OCA, positive control) was orally administered once daily for 3 weeks at a concentration of 30 mg / kg. After the administration was completed, the mice were sacrificed, the livers were excised, and histological analysis was performed using Hematoxylin & Eosin (H&E) staining. The pathological status of liver tissue was analyzed by calculating the NAFLD (non-alcoholic fatty liver disease) activity score using pathological indicators consisting of steatosis, lobular inflammation, and hepatocyte ballooning, and the results were expressed in the format Mean ± SD (Standard Deviation). Statistical analysis was performed using GraphPad Prism 6, and statistical significance compared to the negative control group was indicated as follows: *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001
[0209] As a result of evaluation using STAM mice, the NAFLD activity score in the inabogliflozin administration group decreased by more than 1 point compared to the negative control group, and pathologically, it was confirmed that inabogliflozin had a liver damage improvement effect similar to that of OCA when compared to Obeticholic Acid (OCA, positive control), a drug that inhibits liver damage (Fig. 2b). Therefore, through this example, it was confirmed that inabogliflozin significantly inhibits the pathological progression of MASLD in the STAM model, which suggests that inabogliflozin can be usefully used for the prevention or treatment of liver diseases related to metabolic disorders.
Claims
1. A pharmaceutical composition for the prevention or treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) comprising inabogliflozin as an active ingredient.
2. A pharmaceutical composition for the prevention or treatment of MASLD, wherein the MASLD is accompanied by type 2 diabetes or impaired fasting glucose.
3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is intended for the improvement of a metabolic abnormal state in which the Hepatic Steatosis Index (HSI) exceeds 30 or the Framingham Steatosis Index (FSI) is -1.2 or higher, for the prevention or treatment of MASLD.
4. A pharmaceutical composition for the prevention or treatment of MASLD, wherein, in any one of claims 1 to 3, the pharmaceutical composition is intended for single administration.
5. A pharmaceutical composition for the prevention or treatment of MASLD, wherein, in any one of claims 1 to 3, the pharmaceutical composition is intended for co-administration with metformin.
6. A pharmaceutical composition for the prevention or treatment of MASLD, wherein, in any one of claims 1 to 3, the pharmaceutical composition is intended for co-administration with a DPP4 inhibitor.
7. A pharmaceutical composition for the prevention or treatment of MASLD, wherein the DPP4 inhibitor in claim 6 is gemigliptin.
8. A pharmaceutical composition for the prevention or treatment of MASLD according to any one of claims 1 to 3, wherein the pharmaceutical composition is intended for co-administration with metformin and a DPP4 inhibitor.
9. In any one of claims 1 to 3, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of MASLD administered in combination with a sulfonylurea-based insulin secretion promoter.
10. In any one of claims 1 to 3, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of MASLD administered in combination with insulin.
